북미 수면 장애 치료 시장 – 2028년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

북미 수면 장애 치료 시장 – 2028년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • Feb 2022
  • North America
  • 350 Pages
  • 테이블 수: 78
  • 그림 수: 49

North America Sleep Disorder Treatment Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2021 –2028
Diagram 시장 규모(기준 연도)
USD 4,945.53 Million
Diagram 시장 규모(예측 연도)
USD 9,469.97 Million
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>북미 수면 장애 치료 시장, 유형별(불면증, 수면 무호흡증, 불안 다리 증후군(RLS), 기면증 및 기타), 치료(약리적 치료, 기계적 치료, 하악 전진 장치, 설하 신경 자극기, 수술 및 기타), 투여 경로(경구, 비경구 및 기타), 약물 유형(브랜드 및 제네릭), 인구 유형(어린이 및 성인), 최종 사용자(병원, 전문 클리닉, 홈 헬스케어, 외래 수술 센터 및 기타), 유통 채널(직접 입찰, 병원 약국, 소매 약국, 온라인 약국 및 기타), 국가(미국, 캐나다 및 멕시코) 산업 동향 및 2028년까지의 예측

북미 수면 장애 치료 시장

시장 분석 및 통찰력 : 북미 수면 장애 치료 시장

북미 수면 장애 치료 시장은 2020년 4,945.53백만 달러에서 2028년 9,469.97백만 달러로 성장할 것으로 예상되며, 2021년에서 2028년까지의 예측 기간 동안 8.6%의 CAGR로 성장할 것으로 예상됩니다. 북미 수면 장애 치료 시장은 전 세계적으로 수면 무호흡증, 불면증, 기면증과 같은 수면 장애의 유병률이 증가함에 따라 성장할 것으로 예상됩니다.

수면 무호흡증, 기면증 또는 불면증과 같은 수면 장애는 환자가 수면 유지 또는 수면 시작에 어려움을 겪는 의학적 장애입니다. 이 장애는 불규칙한 정신적, 신체적, 사회적 및 정서적 기능을 유발합니다. 수면 장애는 환자의 증상에 따라 다양한 치료 옵션을 통해 치료됩니다. 대부분의 수면 무호흡증 환자는 기계적 치료를 통해 치료됩니다. 항우울제, 카나비디올, 벤조디아제핀 및 각성제와 같은 약리적 치료는 불면증, 기면증 및 불안 다리 증후군을 치료하는 데 사용됩니다. 구강 내 장치는 적절한 가스 교환을 위한 공간을 만들기 위해 기도 채널을 생성하여 코골이를 예방하는 데에도 사용됩니다.

시장 성장은 우울증 및 기타 의학적 장애의 증가, 전 세계적으로 노인 인구 증가, 라이프스타일 변화, 수면의 질 부족과 같은 요인에 의해 촉진될 것으로 예상되며, 이는 수면 장애 치료 시장 성장을 주도했습니다. 이러한 수면 장애 치료를 위한 새로운 FDA 승인 약물 및 의료 기기의 도입은 수면 장애 치료 시장 성장의 기회로 작용합니다. 그러나 주요 수면 장애 치료 약물의 특허 만료 또는 특허 절벽 및 이러한 약물과 관련된 부작용은 수면 장애 치료 시장 성장을 제한합니다.

The sleep disorder treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

북미 수면 장애 치료 시장

North America Sleep Disorder Treatment Market Scope and Market Size

North America sleep disorder treatment market is segmented on the basis of type, treatment, route of administration, drugs type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the sleep disorder treatment market is segmented into insomnia, sleep apnea, restless legs syndrome (RLS), narcolepsy and others. In 2021, insomnia segment is dominating the market because of the growing awareness about the condition, more and more people are adopting the treatment options.
  • On the basis of treatment, the sleep disorder treatment market is segmented into pharmacological therapy, mechanical therapy, mandibular advancement devices, hypoglossal nerve stimulator, surgery and others. In 2021, pharmacological therapy segment is dominating the market due to increased pipeline products for the treatment of sleep disorders by key market players.
  • On the basis of route of administration, the sleep disorder treatment market is segmented into oral, parenteral and others. In 2021, oral segment is dominating the market due to the economical and safe form of administration leading to increased uptake by the suffered patients.
  • On the basis of drugs type, the sleep disorder treatment market is segmented into branded and generics. In 2021, generics segment is dominating the market because of the economical nature and easy availability of the generics drugs for the treatment of sleep disorder.
  • On the basis of population type, the sleep disorder treatment market is segmented into children and adults. In 2021, adults segment is dominating the market due to availability of the U.S. FDA approved pharmacological therapies for the treatment of sleep disorder in adults.
  • On the basis of end user, the sleep disorder treatment market is segmented into hospitals, specialty clinics, home healthcare, ambulatory surgical center and others. In 2021, hospitals segment is dominating the market as hospitals are the prime location visited by patients for any procedure or surgery.
  • 유통 채널을 기준으로 수면 장애 치료 시장은 직접 입찰, 병원 약국, 소매 약국, 온라인 약국 등으로 세분화됩니다. 2021년에는 직접 입찰 부문이 시장을 지배하고 있는데, 대부분의 시설이 직접 입찰을 통해 약물을 조달하기 때문에 직접 입찰이 의사와 환자의 요구를 충족시키기 때문입니다.

북미 수면 장애 치료 시장

수면 장애 치료 시장 국가 수준 분석

수면 장애 치료 시장을 분석하고, 국가, 유형, 치료, 투여 경로, 약물 유형, 인구 유형, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.

수면 장애 치료 시장 보고서에서 다루는 국가는 미국, 캐나다, 멕시코입니다.

미국은 인구 중 수면 장애의 유병률이 증가함에 따라 시장을 지배할 것으로 예상됩니다. 캐나다는 회사의 제품 포트폴리오가 증가함에 따라 성장할 것으로 예상됩니다. 멕시코는 신흥 시장이며 시장 참여자들이 다양한 제품 제공에 더 집중하고 있기 때문에 성장할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 북미 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

제조업체의 신제품 출시로 수면 장애 치료 시장 참여자들에게 새로운 기회가 창출되고 있습니다.

수면 장애 치료 시장은 또한 수면 장애 치료 산업의 모든 국가별 성장, 수면 장애 치료 시장 판매, 수면 장애 치료 시장 발전의 영향, 수면 장애 치료 시장에 대한 지원과 함께 규제 시나리오의 변화에 ​​대한 자세한 시장 분석을 제공합니다. 이 데이터는 2010년부터 2018년까지의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 수면 장애 치료 시장 점유율 분석

수면 장애 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 수면 장애 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

수면 장애 치료 시장의 주요 기업으로는 Jazz Pharmaceuticals, Inc., Pfizer Inc., Viatris Inc., Arbor Pharmaceuticals, Aurobindo Pharma USA(Aurobindo Pharma의 자회사), sanofi-aventis US LLC(Sanofi의 자회사), Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals, Inc.(Lupin의 자회사), Taj Pharmaceuticals Limited, Eli Lilly and Company, Mallinckrodt, Alembic Pharmaceuticals Limited, Apotex Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceuticals USA, Inc.(Teva Pharmaceutical Industries Ltd.의 자회사), Taro Pharmaceutical Industries Ltd., Koninklijke Philips NV, DeVilbiss Healthcare LLC, ResMed, SomnoMed, Oventus 및 BMC Medical Co. 등이 있습니다.

또한 전 세계 여러 회사에서 많은 제품 출시와 계약을 체결하면서 수면 장애 치료 시장도 가속화되고 있습니다.

예를 들어,

  • 2020년 7월, Jazz Pharmaceuticals plc는 15세 이상의 기면증 환자의 졸음증과 과도한 주간 졸음증에 대한 적응증으로 Xyway라는 약물에 대한 FDA 승인을 발표했습니다. 미국 FDA에서 승인한 이 회사의 새로운 수면 장애 치료제는 시장에서 약물에 대한 수요와 판매를 증가시켜 향후 수익 증가로 이어졌습니다.
  • 2016년 6월, Mylan NV는 수면 무호흡증, 기면증 또는 교대근무 장애와 관련된 과도한 졸음을 가진 성인의 각성 증상에 대한 armodafinil 정제라는 nuvigil 약물의 제네릭 버전을 출시했습니다. 이 회사가 미국 시장에서 출시한 이 신약은 시장에서 수요와 판매를 증가시켜 향후 판매가 증가할 것으로 예상됩니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: REGULATIONS

6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING PREVALENCE OF SLEEPING DISORDERS

7.1.2 RISE IN THE GERIATRIC POPULATION

7.1.3 INCREASE IN MENTAL STRESS DUE TO HECTIC LIFE & UNHEALTHY HABITS

7.1.4 LARGE POOL OF UNDIAGNOSED SLEEP APNEA PATIENTS

7.1.5 PRESENCE OF POTENTIAL CLINICAL PIPELINE CANDIDATES

7.2 RESTRAINTS

7.2.1 SIDE EFFECTS ASSOCIATED WITH THESE DRUGS

7.2.2 PATENT EXPIRATION OF MAJOR SLEEP DISORDER TREATMENT DRUGS

7.2.3 EMERGENCE OF GENERICS

7.3 OPPORTUNITIES

7.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE SLEEP AIDS IN THE U.S.

7.3.2 INCREASING USAGE OF SOCIAL MEDIA AND GROWING ADDICTION OF GADGETS SUCH AS SMARTPHONES AND LAPTOPS

7.3.3 GROWING AWARENESS ABOUT TARGET DISEASE

7.4 CHALLENGES

7.4.1 HIGH COST OF DIAGNOSIS & TREATMENT FOR SLEEPING DISORDER

7.4.2 STRINGENT REGULATORY LANDSCAPE

7.4.3 POTENTIAL ILL-EFFECTS DUE TO DRUG ABUSE

8 IMPACT OF COVID-19 ON NORTH AMERICA SLEEP DISORDER TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.5 CONCLUSION

9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE

9.1 OVERVIEW

9.2 INSOMNIA

9.2.1 INSOMNIA

9.2.2 CHILD INSOMNIA

9.2.3 OTHERS

9.3 SLEEP APNEA

9.3.1 OBSTRUCTIVE SLEEP APNEA

9.3.2 CENTRAL SLEEP APNEA

9.3.3 SNORING

9.3.4 INFANT SLEEP APNEA

9.3.5 OTHERS

9.4 RESTLESS LEGS SYNDROME (RLS)

9.5 NARCOLEPSY

9.5.1 TYPE 1

9.5.2 TYPE 2

10 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 PHARMACOLOGICAL THERAPY

10.2.1 CANNABIDIOL

10.2.2 ANTI-PARKINSONIAN DRUGS (DOPAMINE AGONISTS)

10.2.3 BENZODIAZEPINES

10.2.4 NON-BENZODIAZEPINE

10.2.5 MELATONIN RECEPTOR STIMULATOR

10.2.6 STIMULANTS

10.2.7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)

10.2.8 TRICYCLIC ANTIDEPRESSANTS

10.2.9 SODIUM OXYBATE (XYREM)

10.2.10 OTHERS

10.3 MECHANICAL THERAPY

10.3.1 CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE)

10.3.2 BI-LEVEL PAP

10.3.3 AUTO CPAP OR AUTO BI-LEVEL PAP

10.3.4 ADAPTIVE SERVO-VENTILATION (ASV)

10.4 MANDIBULAR ADVANCEMENT DEVICES

10.5 HYPOGLOSSAL NERVE STIMULATOR

10.6 SURGERY

10.6.1 SOMNOPLASTY

10.6.2 TONSILLECTOMY

10.6.3 NASAL SURGERY

10.6.4 OTHERS

10.7 OTHERS

11 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.2.1 TABLET

11.2.2 PILLS

11.2.3 OTHERS

11.3 PARENTERAL

11.4 OTHERS

12 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE

12.1 OVERVIEW

12.2 GENERICS

12.3 BRANDED

12.3.1 XYREM

12.3.2 EFFEXOR XR

12.3.3 AMBIEN

12.3.4 PRISTIQ

12.3.5 ZENZEDI

12.3.6 VYVANSE

12.3.7 OTHERS

13 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE

13.1 OVERVIEW

13.2 ADULT

13.3 CHILDREN

14 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CLINICS

14.4 HOME HEALTHCARE

14.5 AMBULATORY SURGICAL CENTER

14.6 OTHERS

15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 HOSPITAL PHARMACY

15.4 RETAIL PHARMACY

15.5 ONLINE PHARMACY

15.6 OTHERS

16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY REGION

16.1 NORTH AMERICA

16.1.1 U.S.

16.1.2 CANADA

16.1.3 MEXICO

17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 JAZZ PHARMACEUTICALS, INC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 PRODUCT PORTFOLIO

19.1.4 RECENT DEVELOPMENTS

19.2 PFIZER INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 PRODUCT PORTFOLIO

19.2.4 RECENT DEVELOPMENT

19.3 ELI LILLY AND COMPANY

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 VIATRIS INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 RESMED

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENTS

19.6 MALLINCKRODT

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 KONINKLIJKE PHILIPS N.V.

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 ALEMBIC PHARMACEUTICALS LIMITED

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENT

19.9 AMNEAL PHARMACEUTICALS LLC

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENTS

19.1 APOTEX INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 ARBOR PHARMACEUTICALS

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 BMC MEDICAL CO.

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 DEVILBISS HEALTHCARE LLC

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.15 DR. REDDY’S LABORATORIES LTD.

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 HIKMA PHARMACEUTICALS PLC

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENTS

19.17 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENTS

19.18 OVENTUS

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

19.19 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI)

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 SOMNOMED

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENTS

19.21 TAJ PHARMACEUTICALS LIMITED

19.21.1 COMPANY SNAPSHOT

19.21.2 PRODUCT PORTFOLIO

19.21.3 RECENT DEVELOPMENT

19.22 TARO PHARMACEUTICAL INDUSTRIES LTD.

19.22.1 COMPANY SNAPSHOT

19.22.2 REVENUE ANALYSIS

19.22.3 PRODUCT PORTFOLIO

19.22.4 RECENT DEVELOPMENT

19.23 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

19.23.1 COMPANY SNAPSHOT

19.23.2 REVENUE ANALYSIS

19.23.3 PRODUCT PORTFOLIO

19.23.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

표 목록

TABLE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS FOR SLEEP DISORDER TREATMENT

TABLE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 6 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 9 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 10 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 11 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 12 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 13 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 14 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 34 U.S. SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 35 U.S. INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 36 U.S. SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)

TABLE 37 U.S. NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2019-2028 (USD MILLION)

TABLE 38 U.S. SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 39 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT , 2019-2028 (USD MILLION)

TABLE 40 U.S. MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)

TABLE 41 U.S. SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 42 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 43 U.S. ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 44 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 45 U.S. BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 46 U.S. SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 47 U.S. SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 48 U.S. SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 49 CANADA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 CANADA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 CANADA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)

TABLE 52 CANADA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)

TABLE 53 CANADA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 54 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)

TABLE 55 CANADA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)

TABLE 56 CANADA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 57 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 58 CANADA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 59 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 60 CANADA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 61 CANADA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 62 CANADA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 63 CANADA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 64 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 MEXICO INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 MEXICO SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)

TABLE 67 MEXICO NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)

TABLE 68 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 69 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 70 MEXICO MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 71 MEXICO SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 72 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 73 MEXICO ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 74 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 75 MEXICO BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 76 MEXICO SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)

TABLE 77 MEXICO SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 78 MEXICO SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

그림 목록

FIGURE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION

FIGURE 10 RISING PREVALENCE OF SLEEPING DISORDERS IS EXPECTED TO DRIVE THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 INSOMNIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN 2021 & 2028

FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET

FIGURE 13 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)

FIGURE 14 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)

FIGURE 15 PROPORTION OF AMERICAN TEENS (13- TO 18- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)

FIGURE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020

FIGURE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2028)

FIGURE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020

FIGURE 21 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020-2028 (USD MILLION)

FIGURE 22 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 24 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 25 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 26 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)

FIGURE 27 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 28 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020

FIGURE 29 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020-2028 (USD MILLION)

FIGURE 30 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, CAGR (2020-2028)

FIGURE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, LIFELINE CURVE

FIGURE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020

FIGURE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)

FIGURE 34 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, CAGR (2020-2028)

FIGURE 35 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020

FIGURE 37 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 38 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2028)

FIGURE 39 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 41 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 42 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 43 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 45 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 46 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 48 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE (2020-2028)

FIGURE 49 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY SHARE 2020 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The market is segmented based on , By Type (Insomnia, Sleep Apnea, Restless Legs Syndrome (RLS), Narcolepsy, and Others), Treatment (Pharmacological Therapy, Mechanical Therapy, Mandibular Advancement Devices, Hypoglossal Nerve Stimulator, Surgery, and Others), Route of Administration (Oral, Parenteral, and Others), Drugs Type (Branded and Generics), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, Ambulatory Surgical Center, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S, Canada and Mexico) Industry Trends and Forecast to 2028 .
The North America Sleep Disorder Treatment Market size was valued at USD 4945.53 USD Million in 2020.
The North America Sleep Disorder Treatment Market is projected to grow at a CAGR of 8.6% during the forecast period of 2021 to 2028.